Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

November 6, 2023

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2028

Conditions

Patient SatisfactionDrug AdherenceEfficacy, SelfSafety Issues

Interventions

DRUG

tenofovir alafenamide (TAF)

TAF switch therapy in CHB patients who are unsatisfied to ETV therapy.

Trial Locations (1)

RECRUITING

Taichung Veterans General Hospital, Taichung

All Listed Sponsors

collaborator

Institute of Adherence to Medication

UNKNOWN

lead

Taichung Veterans General Hospital

OTHER

NCT05583006 - Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B | Biotech Hunter | Biotech Hunter